Markets

Nvidia wants to buy in chip design – Sanofi is already expanding

Speculation Ranges: Will Nvidia Grab Arm Holdings? Softbank is considering a sale or an IPO for the chip designer it took over in 2016. The latest quarterly figures confirm Nvidia. The French pharmaceutical company Sanofi has already struck and has secured the US company Principia Biopharma, a specialist in autoimmune diseases.

The most important things about Nvidia and Sanofi in advance:

  • Nvidia relies on a new generation of chips
  • Sanofi wants to grow further through acquisitions

The graphics chip specialist Nvidia wants to expand its business through acquisitions in the Corona crisis and put it on a broader basis. According to media reports, the US company is said to be interested in taking over the British chip designer Arm Holdings. Arm is currently owned by Japanese tech investor Softbank.

Products on Nvidia

According to the information, the talks were already underway. According to insiders, the deal could generate more than $ 32 billion in Softbank’s coffers. That was the sum the Japanese put on the table in 2016 when they swallowed Arm Holdings. In addition to the sale, Softbank is said to have also examined Arm’s IPO. According to market experts, Arm could have waved a valuation of more than $ 40 billion.

The possible acquisition harbors business opportunities for Nvidia. Just recently, Apple announced that it would no longer use Intel processors in its Macs. Instead, the US technology giant wants to fall back on internally designed arm-based chips. As the latest quarterly results show, Nvidia can thus further expand its already significant market position.

Both the profit and the sales growth were better than analysts (FactSet) had expected. For the first time in the company’s history, revenues from business with reindeer centers exceeded those in its core business, the games sector. Nvidia recently presented a new generation of chips for game consoles, which, according to the company, should stimulate growth in this area again.

The pharmaceutical company Sanofi also wants to strengthen areas and therefore take over the US company Principia Biopharma. The two companies have worked closely and often in the past. Sanofi claims that the US company will cost 3.68 billion dollars. The responsible bodies of both companies have already approved the deal. The deal is expected in the fourth quarter.

Products on Sanofi

Sanofi is offering $ 100 per Principia share. The price premium is therefore a relatively low ten percent. However, the price had already risen sharply since July. At the time, rumors of a possible takeover by Sanofi had spread. Since then, the plus has been around a fifth.

Principia Biopharma is a specialist in autoimmune diseases. Among other things, the company has a multiple sclerosis (MS) inhibitor in its pipeline, which Sanofi can access through a takeover. This also includes other active ingredients from the US company.

When purchasing certificates and leverage products, investors should familiarize themselves with how they work and understand the opportunities and risks. Investors should be particularly aware of the increased risks associated with leverage products. In addition, it is essential to pay attention to the creditworthiness and thus to the risk of default of the issuer. You can obtain further important and useful information about our products by calling the toll-free number 0800 4000 910 or on our website www.hsbc-zertifikate.de.

Source: HSBC

Click here for the HSBC homepage

Important instructions

This document was produced by HSBC Trinkaus & Burkhardt AG (“HSBC”). It is for informational purposes only and may not be passed on to third parties without the express written consent of HSBC. The document is a marketing tool. The legal requirements for the impartiality of financial analyzes are not met. There is no prohibition on trading the financial products discussed before this presentation is published (“front running”). The document is also not a substitute for expert investment advice tailored to individual requirements. A subscription offer is also not yet associated with this. The document is only aimed at people who have their permanent residence / seat in Germany or Austria. It is not intended for recipients in other jurisdictions, and especially not for US citizens. Any information given on historical performance (including simulations) as well as forecasts of future performance of the financial products / financial indices presented are not a reliable indicator of future performance. If the discussed financial products are listed in a currency other than EUR, the return may rise or fall due to currency fluctuations. The tax treatment of an investment depends on the personal circumstances of the investor and can be subject to future changes. The information given in this document is based on sources which we believe to be reliable, but which we have not subjected to impartial testing. We do not guarantee and accept no liability for the correctness and completeness of the information contained herein.

Advertising notice

The basic prospectuses as well as the final terms and the basic information sheets are available here. By entering the respective WKN in the search field or via the “Products” tab, you can access the individual product view. There, under “Downloads”, the relevant final terms and conditions for the individual products, which contain the terms and conditions of the offer, including the relevant terms and conditions, as well as the relevant basic information sheets, can be called up for the respective security.

The approval of the base prospectus by the BaFin is not to be understood as its approval of the securities offered. We recommend that interested parties and potential investors read the Base Prospectus and the Final Terms before making an investment decision in order to obtain as much information as possible, in particular about the potential risks and opportunities of the security.

You are about to acquire a product that is not easy and can be difficult to understand.

License notice

“DAX®”, “TecDAX®”, “MDAX®”, “VDAX-NEW®”, “SDAX®”, “DivDAX®”, “ÖkoDAX®”, “Entry Standard Index”, “X-DAX®” and “GEX®” are the intellectual property (including registered trademarks) of Deutsche Börse AG (“DBAG”), Deutsche Börse Group or their licensors and are used under license. The securities are neither promoted, advertised, distributed or supported in any other way by DBAG, Deutsche Börse Group or their licensors, research partners or data suppliers, and DBAG, Deutsche Börse Group and their licensors, research partners or data suppliers assume no warranty and exclude any guarantee Liability (from negligent as well as from other conduct) in this regard generally from and in particular with regard to any errors, omissions or disturbances of the relevant index or the data contained therein.

EURO STOXX 50®, STOXX 50®, STOXX® 600 and its brands, STOXX® Europe 600 Oil & Gas, STOXX® Europe 600 Basic Resources, EURO STOXX 50® DVP are the intellectual property (including registered trademarks) of STOXX Ltd., Zug, Switzerland (“STOXX”), Deutsche Börse Group or its licensors and is used under license. The securities are neither promoted, advertised, distributed or supported in any other way by STOXX, Deutsche Börse Group or their licensors, research partners or data suppliers, and STOXX, Deutsche Börse Group and their licensors, research partners or data suppliers assume no warranty and exclude any guarantee Liability (from negligent as well as from other conduct) in this regard generally from and in particular with regard to any errors, omissions or disturbances of the relevant index or the data contained therein.

The S&P 500 Index is a product of S&P Dow Jones Indices LLC (“SPDJI”) and has been licensed for use by HSBC Trinkaus & Burkhardt AG (“Licensee”). Standard & Poor’s®, S & P® and S&P 500® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”), and Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”). These trademarks have been licensed for use by SPDJI and have been re-licensed by the licensee for certain purposes. Licensee’s products are not sponsored, endorsed, sold or advertised by SPDJI, Dow Jones, S&P or their respective affiliates, and neither party makes any representation as to the advisability of investing in such product (s) and assumes no liability for any errors, omissions or interruptions in the S&P 500 Index.

Nasdaq® and Nasdaq-100 Index® are registered trademarks of Nasdaq, Inc. (together with its affiliated companies referred to as the “Companies”) and licensed to HSBC Trinkaus & Burkhardt AG for use. The companies make no statements about the legality or suitability of the securities. The companies do not issue, recommend, sell or advertise the securities. THE COMPANIES MAKE NO WARRANTIES AND ASSUME NO LIABILITY IN CONNECTION WITH THE SECURITIES.

The “Dow Jones Industrial Average” is a product of S&P Dow Jones Indices LLC (“SPDJI”) and has been licensed for use by HSBC Trinkaus & Burkhardt AG (“Licensee”). Standard & Poor’s® and S & P® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”), and DJIA®, The Dow®, Dow Jones® and Dow Jones Industrial Average are trademarks of Dow Jones Trademark Holdings LLC (“Dow Jones”). These trademarks have been licensed for use by SPDJI and have been re-licensed by the licensee for certain purposes. Licensee’s products are not sponsored, endorsed, sold or advertised by SPDJI, Dow Jones, S&P or their respective affiliates, and neither party makes any representation as to the advisability of investing in such product (s) and assumes no liability for any errors, omissions or interruptions in the Dow Jones Industrial Average.

Editor: HSBC Trinkaus & Burkhardt AG, Königsallee 21/23, 40212 Düsseldorf

Tags

Related Articles

Back to top button
Close
Close